Treatment of Metastatic Non-Small Cell Lung Cancer

In general, which doublet chemotherapy regimen (alone or with a biologic agent) is your first-line treatment choice for a patient with metastatic NSCLC and a good performance status?

In general, which doublet chemotherapy regimen (alone or with a biologic agent) is your first-line treatment choice for a patient with metastatic NSCLC and a good performance status? (continued)

Which of the following therapies have you used with bevacizumab in the treatment of NSCLC?(May have more than one response)

Which of the following therapies have you used with bevacizumab in the treatment of NSCLC? (May have more than one response) (continued)

I generally don’t use bevacizumab in thetreatment of:

I generally don’t use bevacizumab in thetreatment of: (continued)

I generally don’t use bevacizumab in the management of:

For patients with advanced NSCLC who demonstrate stable disease after six cycles of chemotherapy with bevacizumab, I continue bevacizumab as maintenance therapy.

Percent of patients in your practice each year with metastatic NSCLC who are eligible to receive bevacizumab.

Number of patients with advanced NSCLC you have treated with bevacizumab within the past year.

A female never smoker presents with a previously untreated metastatic adenocarcinoma with BAC features and bone and adrenal involvement. Her PS is 1, and end organ function is normal. She wants to be aggressive with treatment. Which of the following regimens would you most likely recommend for this patient at the following ages?

A female never smoker presents with a previously untreated metastatic adenocarcinoma with BAC features and bone and adrenal involvement. Her PS is 1, and end organ function is normal. She wants to be aggressive with treatment. Which of the following regimens would you most likely recommend for this patient at the following ages?

Which of the following regimens would you most likely recommend for a patient who is a 40 pack-year former smoker with previously untreated metastatic NSCLC, previously functioning normally and now with PS 2 because of tumor-related symptoms, at the following ages?

Which of the following regimens would you most likely recommend for a patient who is a 40 pack-year former smoker with previously untreated metastatic NSCLC, previously functioning normally and now with PS 2 because of tumor-related symptoms, at the following ages? (continued)

Have you used bevacizumab in combination with erlotinib off protocol in the treatment of advanced NSCLC (either combined with chemotherapyor not)?

BeTA: A Phase III placebo-controlled, randomized study of erlotinib with or without bevacizumab as second-line therapy for advanced nonsquamous NSCLC

From approximately how many NSCLC tumors have you sent tissue for the following analyses? (Median)

Are you aware of the Phase III trial results presented at ASCO 2008 evaluating cetuximab with chemotherapy for patients with advanced NSCLC?

FLEX: A randomized, multicenter, Phase III study of cisplatin/vinorelbine (CV) with cetuximab versus CV alone in the first-line treatment of advanced NSCLC

If you are aware of the Phase III trial results presented at ASCO 2008, how would you categorize the following? Response from survey participants familiar with FLEX study presented at ASCO 2008

If you are aware of the Phase III trial results presented at ASCO 2008, how would you categorize the following? Response from all survey participants (continued)

FLEX: Efficacy analysis and adverse event results

Are you aware of the Phase III trial results presented at ASCO 2008 evaluating maintenance pemetrexed after induction therapy for patients with Stage III/IV NSCLC?

Phase III study of pemetrexed with best supportive care (BSC) versus placebo with BSC for patients with Stage IIIB/IV NSCLC without disease progression after four cycles of platinum-containing induction therapy

A patient with a Stage IV NSCLC and a good performance status who has stable disease after four cycles of carboplatin/ gemcitabine chemotherapy should receive maintenance pemetrexed chemotherapy.

A patient with a Stage IV NSCLC and a good performance status who has stable disease after four cycles of carboplatin/ gemcitabine chemotherapy should receive maintenance pemetrexed chemotherapy. (continued)

Phase III study of pemetrexed with best supportive care (BSC) versus placebo with BSC: Efficacy data

Phase III study of pemetrexed with best supportive care (BSC) versus placebo with BSC: Efficacy data (continued)

A 60-year-old former smoker demonstrates an excellent response to carboplatin/ paclitaxel/ bevacizumab as first-line therapy for metastatic disease and is continued on bevacizumab. At 16 months, the patient develops slow but definite disease progression. Outside of a protocol setting, this patient should be offered which of the following regimens?

A 60-year-old former smoker demonstrates an excellent response to carboplatin/ paclitaxel/ bevacizumab as first-line therapy for metastatic disease and is continued on bevacizumab. At 16 months, the patient develops slow but definite disease progression. Outside of a protocol setting, this patient should be offered which of the following regimens? (continued)